Zolinza (vorinostat) — Medica
Classic Hodgkin Lymphoma
Initial criteria
- age ≥ 18 years
- patient has tried at least three systemic regimens (e.g., ABVD + rituximab, CHOP + rituximab, CVbP + rituximab, Adcetris + AVD)
- medication is used in combination with Keytruda (pembrolizumab intravenous infusion)
Approval duration
1 year